Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exemestane - Pfizer

Drug Profile

Exemestane - Pfizer

Alternative Names: Aromasil; Aromasin; Aromasine; FCE 24304; Nikidess; PNU 155971

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Emory University; German Breast Group; Pfizer
  • Class Androstadienes; Antineoplastics; Small molecules
  • Mechanism of Action Aromatase inhibitors; Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer

Most Recent Events

  • 07 Dec 2021 Efficacy data from the phase III SOFT and TEXT trials presented at the 44th Annual San Antonio Breast Cancer Symposium (SABCS-2021)
  • 12 Jun 2018 German Breast Group and Pfizer completes a phase III trial in Breast cancer (Male breast cancer, Combination therapy, Adjuvant therapy, Neoadjuvant therapy) in Germany (PO) (NCT01638247) (EudraCT2009-015122-11)
  • 22 Jan 2018 Pfizer completes a phase III trial in Breast cancer (Prevention) in USA, Canada, Puerto Rico and France (PO) (NCT00083174)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top